Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

1156 - Capecitabine (cape) dosing using skeletal muscle index (SMI) compared to body surface area (BSA)

Date

08 Oct 2016

Session

Poster Display

Presenters

Julia Sun

Citation

Annals of Oncology (2016) 27 (6): 149-206. 10.1093/annonc/mdw370

Authors

J. Sun1, A. Ilich2, C. Kim3, G. Wong2, S. Ghosh2, J. Spratlin2, K. Mulder2, M. Danilak2, C. Chambers2, M. Sawyer2

Author affiliations

  • 1 Medical Oncology, University of Alberta Cross Cancer Institute, T6G 1Z2 - Edmonton/CA
  • 2 Medical Oncology, University of Alberta Cross Cancer Institute, Edmonton/CA
  • 3 Medical Oncology, CancerCare Manitoba MacCharles, Winnipeg/CA
More

Resources

Abstract 1156

Background

Cape doses used to treat colorectal (CRC) and breast cancer (BC) are calculated using BSA. Cape dose is 1250 mg/m2 in CRC and 1000 mg/m2 in BC. Using BSA to calculate cape dose does not consider body composition. We hypothesize that differences in cape doses between CRC and BC patients (pts) is due to body composition differences between males (M) and females (F), not cancer type. Furthermore, low skeletal muscle density (SMD) is prognostic of poor survival in advanced cancers. As a secondary objective, we set out to determine if SMD was prognostic of outcomes in early stage CRC.

Methods

We performed a retrospective study of all pts diagnosed with early stage CRC treated with adjuvant cape from 2008-2012. Data was collected on demographics and cape doses at cycles 1 and 3. SMI and SMD were calculated using baseline CT scans.

Results

183 pts (101 M, 82 F) were identified. F received higher starting cape doses compared to M based on SMI. Mean cape/SMI dose was 5107.4 mg/cm2/m2 (SD 1113.8) for F compared to 4711.9 mg/cm2/m2 (SD 870.6) for M (p = 0.009). At cycle 3, F still had higher doses of 3875.1 mg/cm2/m2 (SD 1663.5), but did not differ statistically from M pts at 3691.6 mg/cm2/m2 (SD 1629.5) (p = 0.5). Median recurrence free survival (RFS) for low SMD pts compared to high SMD pts was 72.8 vs 76.9 months (hazard ratio [HR] 1.80; p = 0.06). Patients with lower SMD were at higher risk of death (HR 2.81; p = 0.05); median overall survival was not reached.

Conclusions

F received higher cape doses/SMI than M at the CRC 1250 mg/m2 dose. After adjusting cape doses for DLTs, M and F CRC pts received the same cape dose/SMI. Our results suggest differences between CRC and BC cape dosing may be a consequence of body composition differences between M and F pts. SMI may be more useful than BSA when calculating cape doses. Our study showed low SMD was prognostic for OS probability and trended towards significance for RFS in adjuvant CRC pts.

Clinical trial identification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

J. Spratlin: Conducted research project funded by Roche in the past 2 years. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings